Literature DB >> 23872061

A simple, robust and highly efficient transient expression system for producing antibodies.

Tom Vink1, Maroeska Oudshoorn-Dickmann2, Marcel Roza2, Jelte-Jan Reitsma2, Rob N de Jong2.   

Abstract

Transient expression systems in mammalian cells have become the method of choice for producing research quantities of antibodies. Both the speed and yield of the available transient systems and the natural posttranslational modifications favor these systems above expression in lower eukaryotes, prokaryotes or stable cell lines. We describe an optimized mammalian transient expression system, capable of producing up to 400mg/L of native secreted antibodies in less than a week. The system is composed of commercially available components and is based on expression in the fast growing suspension cell line, FreeStyle™ 293-F (HEK-293F). The method depends on an optimal combination of a gene transfer method, an expression vector and cotransfection with expression enhancing plasmids, encoding the large T antigen of the SV40 virus and the cell cycle inhibitors p21 and p27. Optimization of all components of the expression system, by experimental design techniques, yielded maximal expression levels (including antibody isotypes IgG1, 2, 3, 4 and Fab fragments of various species). Expression volumes were scalable from 0.1 ml up to 1.2L in a simple shaker flask system in animal component free, low protein medium, enabling consistent production of relatively high amounts of a large number of native antibodies.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  293Fectin; 293fectin™; Antibody; CMV; Cell cycle; DoE; Experimental design; FreeStyle™ 293 expression medium; FreeStyle™ 293-F; HC; HEK-293; HEK-293F; HEK293; LC; Medium; Optimem; SV40 large T antigen; SVLT; Transient expression; antibody heavy chain; antibody light chain; cyclin-dependent kinase inhibitor 1; cyclin-dependent kinase inhibitor 1B; cytomegalo virus; design of experiments; human embryonic kidney 293 cell line; opti-MEM® I reduced-serum medium; p21; p27; the large T antigen of the SV40 virus

Mesh:

Substances:

Year:  2013        PMID: 23872061     DOI: 10.1016/j.ymeth.2013.07.018

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  40 in total

1.  An anti-apoptotic HEK293 cell line provides a robust and high titer platform for transient protein expression in bioreactors.

Authors:  Tia A Arena; Bernice Chou; Peter D Harms; Athena W Wong
Journal:  MAbs       Date:  2019-04-24       Impact factor: 5.857

2.  A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.

Authors:  Esther Drent; Maria Themeli; Renée Poels; Regina de Jong-Korlaar; Huipin Yuan; Joost de Bruijn; Anton C M Martens; Sonja Zweegman; Niels W C J van de Donk; Richard W J Groen; Henk M Lokhorst; Tuna Mutis
Journal:  Mol Ther       Date:  2017-05-13       Impact factor: 11.454

3.  Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.

Authors:  Niels Heemskerk; Mandy Gruijs; A Robin Temming; Marieke H Heineke; Dennis Y Gout; Tessa Hellingman; Cornelis W Tuk; Paula J Winter; Suzanne Lissenberg-Thunnissen; Arthur Eh Bentlage; Marco de Donatis; Marijn Bögels; Thies Rösner; Thomas Valerius; Jantine E Bakema; Gestur Vidarsson; Marjolein van Egmond
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

4.  Controlled Fab-arm exchange for the generation of stable bispecific IgG1.

Authors:  Aran F Labrijn; Joyce I Meesters; Patrick Priem; Rob N de Jong; Ewald T J van den Bremer; Muriel D van Kampen; Arnout F Gerritsen; Janine Schuurman; Paul W H I Parren
Journal:  Nat Protoc       Date:  2014-09-25       Impact factor: 13.491

5.  Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

Authors:  Erika M Cook; Margaret A Lindorfer; Hilma van der Horst; Simone Oostindie; Frank J Beurskens; Janine Schuurman; Clive S Zent; Richard Burack; Paul W H I Parren; Ronald P Taylor
Journal:  J Immunol       Date:  2016-07-29       Impact factor: 5.422

6.  Mucin-coating technologies for protection and reduced aggregation of cellular production systems.

Authors:  Carolyn R Shurer; Shelby E Head; Marc C Goudge; Matthew J Paszek
Journal:  Biotechnol Bioeng       Date:  2019-02-19       Impact factor: 4.530

7.  Affinity of human IgG subclasses to mouse Fc gamma receptors.

Authors:  Gillian Dekkers; Arthur E H Bentlage; Tamara C Stegmann; Heather L Howie; Suzanne Lissenberg-Thunnissen; James Zimring; Theo Rispens; Gestur Vidarsson
Journal:  MAbs       Date:  2017-05-02       Impact factor: 5.857

8.  High Yield Expression of Recombinant Human Proteins with the Transient Transfection of HEK293 Cells in Suspension.

Authors:  Ganesh P Subedi; Roy W Johnson; Heather A Moniz; Kelley W Moremen; Adam Barb
Journal:  J Vis Exp       Date:  2015-12-28       Impact factor: 1.355

Review 9.  Better and faster: improvements and optimization for mammalian recombinant protein production.

Authors:  Steven C Almo; James D Love
Journal:  Curr Opin Struct Biol       Date:  2014-04-12       Impact factor: 6.809

10.  Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

Authors:  Julia Boshuizen; Louise A Koopman; Oscar Krijgsman; Aida Shahrabi; Elke Gresnigt- van den Heuvel; Maarten A Ligtenberg; David W Vredevoogd; Kristel Kemper; Thomas Kuilman; Ji-Ying Song; Nora Pencheva; Jens Thing Mortensen; Marnix Geukes Foppen; Elisa A Rozeman; Christian U Blank; Maarten L Janmaat; David Satijn; Esther C W Breij; Daniel S Peeper; Paul W H I Parren
Journal:  Nat Med       Date:  2018-01-15       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.